<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-QSB
[X] Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the quarterly period ended September 30, 1997
or
[ ] Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
For the transition period from______________________to______________________
Commission File Number 0-9570
LUTHER MEDICAL PRODUCTS, INC.
(Exact name of small business issuer as specified in its charter)
CALIFORNIA 33-0468235
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
14332 CHAMBERS ROAD, TUSTIN, CA 92780
(Address of principal executive offices) (Zip Code)
(714) 544-3002
(Issuer's telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last
report.)
Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements for the past
90 days.
[X] Yes [ ] No
Indicate the number of shares outstanding of each of the issuer's classes of
common stock, as of the latest practicable date.
Common Stock No Stated Par Value--3,262,786 shares as of September 30, 1997
<PAGE>
INDEX
LUTHER MEDICAL PRODUCTS, INC.
PART I - FINANCIAL INFORMATION
<TABLE>
<S> <C>
Condensed Balance Sheet - September 30, 1997 3
Condensed Statements of Operations - Three months ended September 30,
1997 and 1996 4
Condensed Statements of Cash Flows
Three months ended September 30, 1997 and 1996 5
Notes to Condensed Consolidated Financial Statements 6
Management's Discussion and Analysis of Financial
Condition and Results of Operations 7
PART II - OTHER INFORMATION 8
Signature Page 8
</TABLE>
<PAGE>
LUTHER MEDICAL PRODUCTS, INC.
CONDENSED BALANCE SHEET
<TABLE>
<CAPTION>
SEPT. 30, 1997
<S> <C>
ASSETS
CURRENT ASSETS
Cash and cash equivalents $ 596,771
Accounts receivable - net 829,056
Inventories - Note C 1,990,775
Other current assets 95,316
-----------
TOTAL CURRENT ASSETS 3,511,918
-----------
PROPERTY AND EQUIPMENT 1,283,995
Less accumulated depreciation (952,068)
-----------
PROPERTY AND EQUIPMENT - NET 331,927
INTANGIBLE ASSETS - NET 81,315
OTHER ASSETS 10,199
-----------
$ 3,935,359
===========
LIABILITIES & STOCKHOLDERS' EQUITY
CURRENT LIABILITIES
Accounts payable $ 276,467
Accrued payroll and related expenses 87,521
Other accrued liabilities 57,806
-----------
TOTAL CURRENT LIABILITIES 421,794
-----------
STOCKHOLDERS' EQUITY
Preferred stock - no stated par value;
10,000,000 shares authorized; none issued
Common stock - no stated par value;
25,000,000 shares authorized; issued and
outstanding 3,262,786 10,537,479
Note receivable from shareholders (235,409)
Accumulated deficit (6,788,505)
-----------
NET STOCKHOLDERS' EQUITY 3,513,565
-----------
$ 3,935,359
===========
</TABLE>
See notes to condensed financial statements.
-3-
<PAGE>
LUTHER MEDICAL PRODUCTS, INC.
CONDENSED STATEMENT OF OPERATIONS
FOR THE QUARTER ENDED SEPTEMBER 30,
<TABLE>
<CAPTION>
Three Months Three Months
ended 1997 ended 1996
------------ ------------
<S> <C> <C>
REVENUES $1,471,843 $1,132,108
COSTS AND EXPENSES:
Cost of sales 804,294 664,424
Selling 272,774 325,771
General and administrative 185,117 188,580
Research and development 132,204 123,665
Depreciation and amortization 52,779 60,106
---------- ----------
TOTAL COSTS AND EXPENSES 1,447,168 1,362,546
NET INCOME (LOSS) 24,675 (230,438)
========== ==========
Weighted average number of
shares outstanding 3,196,000 3,179,000
Net income (loss) per share $.01 $(.07)
</TABLE>
See notes to condensed financial statements.
-4-
<PAGE>
LUTHER MEDICAL PRODUCTS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED SEPTEMBER 30
<TABLE>
<CAPTION>
1997 1996
--------- ----------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 24,674 $ (230,438)
Adjustments to reconcile net loss to net cash
used by operating activities :
Depreciation and amortization 52,779 60,106
Changes in operating assets and liabilities:
Accounts and other receivables (3,692) 116,601
Inventories (147,350) (162,269)
Prepaid expenses and other assets (35,738) (584)
Accounts payable (15,093) (13,434)
Accrued payroll and related expenses (28,017) (6,921)
Other accrued liabilities (25,478) 18,187
--------- ----------
Net cash used in operating activities (177,915) (218,752)
--------- ----------
INVESTING ACTIVITIES:
Purchases of property and equipment (37,288) (37,007)
--------- ----------
Net cash used in investing activities (37,288) (37,007)
--------- ----------
FINANCING ACTIVITIES:
Proceeds from sales of common stock -0- 32,272
Net cash provided by financing activities -0- 32,272
--------- ----------
Net decrease in cash (215,203) (223,487)
Cash, beginning of year 811,974 1,598,141
--------- ----------
Cash, at end of three months $ 596,771 $1,374,654
========= ==========
</TABLE>
See notes to condensed financial statements
-5-
<PAGE>
LUTHER MEDICAL PRODUCTS, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
SEPTEMBER 30, 1997
NOTE A - BASIS OF PREPARATION
The accompanying condensed consolidated financial statements have been prepared
in accordance with generally accepted accounting principles for interim
financial information and with the instructions to Form 10-QSB and Article 10 of
Regulation S-B. Accordingly, they do not include all of the information and
footnotes required by generally accepted accounting principles for complete
financial statements. In the opinion of management, all adjustments (consisting
of normal recurring accruals) considered necessary for a fair presentation have
been included. Operating results for the three month period ending September
30, 1997 are not necessarily indicative of the results that may be expected for
the year ended June 30, 1998. For further information, refer to the
consolidated financial statements and footnotes thereto included in the
Company's Annual Report on Form 10-KSB.
NOTE B - EARNINGS (LOSS) PER SHARE
Loss per share is calculated using the weighted average number of common shares
and common share equivalents outstanding. Common stock equivalents are not
included because their effect would be immaterial.
NOTE C - INVENTORIES
The components of inventory consist of the following:
<TABLE>
<CAPTION>
Sept. 30, 1997
--------------
<S> <C>
Raw material $ 804,760
Work in process 531,938
Finished goods 654,077
----------
$1,990,775
==========
</TABLE>
NOTE D - INCOME TAX
No provision for income taxes has been recorded for the quarter ended September
30, 1997 because the Company expects to use available operating loss
carryforwards to offset taxable income for the year.
-6-
<PAGE>
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS
Results of operations
Total consolidated revenues for the first quarter of fiscal year 1998 increased
30% to $1,472,000 from $1,132,000 for the prior year's quarter. Domestic product
sales contributed $1,078,000, a 39% increase from $774,000 for the same period
last year, of which Long Term Peripheral Catheter sales, a new product line
introduced in the second quarter of fiscal year 1997, were $113,000. Sales of
the tracheostomy products increased to $89,000 from $3,000 in the previous
year's quarter. Product sales to international distributors increased 19% to
$222,000 compared to $187,000 during last year's quarter. OEM sales were
$157,000 for the quarter ended September 30, 1997, compared to $147,000 for the
prior year's quarter. Other income decreased by $9,000.
Cost of revenues as a percentage of net sales for three months ended September
30, 1997, decreased to 54.6% from 58.7% for the prior year's quarter, mainly as
a result of lower manufacturing costs per unit due to higher production volume.
Selling expenses decreased by $53,000 for the quarter, as a result of
terminating two contracts for marketing services, one in November 1996 and one
in January 1997. General and administrative expenses decreased by $3,000 for the
quarter. Research and development expenses increased by $8,500 for the quarter
as a result of higher patent expenses. Depreciation and amortization expense
decreased by $7,000 for the quarter due to reduced depreciation expenses.
Liquidity and Capital Resources
At September 30, 1997, the Company had working capital of $3.1 million and its
principal sources of liquidity consisted of $597,000 in cash. Net cash used by
operating activities for the three months ended March 31, 1997, was $178,000,
mainly as the result of increased inventories. With respect to investing
activities, the Company made purchases of property and equipment totaling
$37,000.
The Company has no long-term commitments other than an annual lease obligation
of $130,000 for its facilities through 1998.
-7-
<PAGE>
PART II - OTHER INFORMATION
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits
None
(b) Reports on Form 8-K
Form 8-K, dated July 2, 1997, reporting change of the Company's principal
accountants, effective June 30, 1997.
SIGNATURES
In accordance with the requirements of the Securities Exchange Act, the
Registrant caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
LUTHER MEDICAL PRODUCTS, INC.
By: /s/ David Rollo Date: November 4, 1997
--------------- -----------------------
David Rollo
Chief Financial Officer
-8-
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> JUN-30-1997
<PERIOD-END> SEP-30-1997
<CASH> 596,771
<SECURITIES> 0
<RECEIVABLES> 829,056
<ALLOWANCES> 0
<INVENTORY> 1,990,775
<CURRENT-ASSETS> 3,511,918
<PP&E> 1,283,995
<DEPRECIATION> 952,068
<TOTAL-ASSETS> 3,935,359
<CURRENT-LIABILITIES> 421,794
<BONDS> 0
0
0
<COMMON> 10,537,479
<OTHER-SE> (235,409)
<TOTAL-LIABILITY-AND-EQUITY> 3,935,359
<SALES> 1,471,843
<TOTAL-REVENUES> 1,471,843
<CGS> 804,294
<TOTAL-COSTS> 1,447,168
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> 24,675
<INCOME-TAX> 0
<INCOME-CONTINUING> 24,675
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 24,675
<EPS-PRIMARY> $.01
<EPS-DILUTED> 0
</TABLE>
